Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs
Synopsis
The company said that Dr. Reddy’s Laboratories has agreed not to market a generic version of either Nexletol or Nexlizet in the U.S. before April 19, 2040.
Esperion Therapeutics (ESPR) on Friday said that it has entered into a settlement agreement with Dr. Reddy’s Laboratories under which the latter has agreed not to market a generic version of either Nexletol or Nexlizet in the United States before April 19, 2040.
The agreement resolves the patent litigation brought by Esperion against Dr. Reddy’s Laboratories after it submitted an Abbreviated New Drug Application seeking approval to market a generic version of each of Nexletol and Nexlizet.
The two drugs are used to reduce low-density lipoprotein (LDL) or "bad" cholesterol in adults with high blood cholesterol levels, known as primary hyperlipidemia. Shares of Esperion traded 3% higher in the pre-market session at the time of writing.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.